AbbVie Pre-Tax Profit Margin 2010-2023 | ABBV

Current and historical pre-tax profit margin for AbbVie (ABBV) from 2010 to 2023. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. AbbVie pre-tax profit margin for the three months ending December 31, 2023 was .
AbbVie Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2023-12-31 $54.32B $6.25B 11.51%
2023-09-30 $55.14B $8.00B 14.51%
2023-06-30 $56.02B $10.45B 18.65%
2023-03-31 $56.74B $9.02B 15.90%
2022-12-31 $58.05B $13.48B 23.21%
2022-09-30 $57.82B $14.78B 25.57%
2022-06-30 $57.35B $14.07B 24.54%
2022-03-31 $56.73B $14.05B 24.77%
2021-12-31 $56.20B $12.99B 23.11%
2021-09-30 $55.17B $7.21B 13.07%
2021-06-30 $53.73B $6.02B 11.21%
2021-03-31 $50.20B $4.17B 8.30%
2020-12-31 $45.80B $3.40B 7.42%
2020-09-30 $40.65B $7.98B 19.63%
2020-06-30 $36.23B $7.48B 20.65%
2020-03-31 $34.06B $8.98B 26.37%
2019-12-31 $33.27B $8.43B 25.33%
2019-09-30 $32.87B $2.98B 9.06%
2019-06-30 $32.62B $3.74B 11.46%
2019-03-31 $32.65B $4.94B 15.14%
2018-12-31 $32.75B $5.20B 15.87%
2018-09-30 $32.19B $8.76B 27.23%
2018-06-30 $30.95B $8.10B 26.16%
2018-03-31 $29.61B $8.44B 28.50%
2017-12-31 $28.22B $7.73B 27.39%
2017-09-30 $27.27B $8.53B 31.28%
2017-06-30 $26.71B $8.45B 31.64%
2017-03-31 $26.22B $8.19B 31.25%
2016-12-31 $25.64B $7.88B 30.75%
2016-09-30 $25.24B $7.81B 30.94%
2016-06-30 $24.75B $7.44B 30.07%
2016-03-31 $23.78B $7.03B 29.55%
2015-12-31 $22.86B $6.65B 29.07%
2015-09-30 $21.91B $3.68B 16.81%
2015-06-30 $20.99B $2.72B 12.98%
2015-03-31 $20.44B $2.48B 12.13%
2014-12-31 $19.96B $2.37B 11.87%
2014-09-30 $19.62B $4.85B 24.70%
2014-06-30 $19.26B $5.44B 28.27%
2014-03-31 $19.02B $5.38B 28.27%
2013-12-31 $18.79B $5.33B 28.38%
2013-09-30 $18.89B $5.61B 29.68%
2013-06-30 $18.74B $5.92B 31.62%
2013-03-31 $18.54B $5.96B 32.14%
2012-12-31 $18.38B $5.73B 31.15%
2012-09-30 $18.04B $6.82B 37.82%
2012-06-30 $17.94B $5.22B 29.09%
2012-03-31 $17.72B $3.82B 21.53%
2011-12-31 $17.44B $3.67B 21.03%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $294.653B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $690.114B 114.92
Novo Nordisk (NVO) Denmark $550.665B 45.36
Johnson & Johnson (JNJ) United States $356.431B 14.14
Merck (MRK) United States $318.604B 83.85
AstraZeneca (AZN) United Kingdom $212.533B 18.83
Novartis AG (NVS) Switzerland $200.005B 13.86
Pfizer (PFE) United States $147.226B 14.21
Sanofi (SNY) $117.121B 10.55
Innoviva (INVA) United States $0.945B 6.67